Showing 2331-2340 of 9108 results for "".
"Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leSCALE 2024: Dr. Linda Stein Gold on Benzyne Release From Benzyl Peroxide
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-linda-stein-gold-benzyne-release-from-benzyl-peroxide/26373/Linda Stein Gold, MD, discusses the new information on benzyl peroxide and its implications at Music City SCALE.Mechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,ISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.From Diagnosis to Prognosis: Using MyPath® Melanoma and DecisionDx®-Melanoma to Help Guide Patient Management Decisions
https://practicaldermatology.com/programs/practical-dermatology/from-diagnosis-to-prognosis-using-mypath-melanoma-and-decisiondx-melanoma-to-help-guide-patient-management-decisions/39944/Gene Expression Profile Testing Helps Clinicians Clarify Diagnostically Ambiguous Lesions and Deliver Personalized, Risk-Aligned Melanoma CareDifferentiating Prurigo Nodularis Lesions
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/differentiating-prurigo-nodularis-lesions/48787/James Q. Del Rosso, DO, FAOCD, discusses clinical pearls to help distinguish prurigo nodularis from other pruritic dermatoses during initial evaluation.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aDWTV Extra: Remembering Dr. Robert Sidbury
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-remembering-dr-robert-sidbury/36520/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD; Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD; and Board Member Peter A. Lio, MD, FAAD, reflect on the life and career of their colleague Robert Sidbury, MD, MPH, who passed away suddenly at the age of 61.DermwireTV: Pharma Partnership Boosts Spesolimab, Plus More
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-pharma-partnership-boosts-spesolimab-plus-more/36519/In this episode of Dermwire TV, two pharma leaders partner to commercialize SPEVIGO for patients with generalized pustular psoriasis; interest in red light devices is up; and experts take a look at what’s new in psoriasis treatments on the Practical Dermatology Podcast.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/videos/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin and